Gilead Sciences Inc is nearing a deal to buy biopharmaceutical company Immunomedics Inc for more than $20 billion in a deal that would further expand Gilead’s portfolio of cancer treatments, the Wall Street Journal reported on Saturday.
Source: Gilead nears deal to buy Immunomedics for more than $20 billion, WSJ reports | Reuters
